DeCure for Striatal degeneration, autosomal dominant 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for striatal degeneration, autosomal dominant 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleStriatal degeneration, autosomal dominant 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for striatal degeneration, autosomal dominant 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 10A (PDE10A) — PDE10A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1,3-thiazol-5-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4DFF · 2.11 Å · ligand 8,9-dimethoxy-1-(1,3-thiazol-5-yl)-5,6-dihydroimidazo[5,1-a]isoquinoline (0JP). Experimental structure, not a prediction.
What the evidence adds up to
A 2014 review argues that no disease-modifying drugs exist for any age-associated neurodegenerative disease, including striatal degeneration, and that the single-target approach based on rare dominant mutations is unlikely to succeed. The author recommends phenotypic screening assays that reflect the biology of the aging brain instead. This is a general argument, not a study of the specific disease.
A 1988 case report describes a family with autosomal dominant Alzheimer’s disease, not striatal degeneration. Twelve individuals across four generations were affected, with onset in the late 30s to early 40s and death by age 50. The report notes that 20 members of generation IV and 9 of generation V face an apparent 50% risk of developing the disease. This paper does not address striatal degeneration.
A 2017 study in mice shows that heterozygous deletion of SYNJ1, a gene linked to recessive early-onset atypical Parkinsonism, causes age-dependent decline of SYNJ1 expression in the striatum and striatal dopaminergic terminals. SYNJ1+/− mice develop progressive behavioural alterations and dopaminergic terminal degeneration. The authors also found down-regulation of human SYNJ1 transcripts in a subset of sporadic Parkinson’s disease brains. This study does not test any drug and does not involve autosomal dominant striatal degeneration.
No drug is tested or proposed in any of these abstracts for striatal degeneration, autosomal dominant 2. What is missing is any clinical trial, any phenotypic screening applied to this specific disease, any patient-derived cell or animal model of the mutation, and any funding or systematic effort to repurpose a compound for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
ACS Chemical Neuroscience · 2014 · 103 citations · open access
Back to the Future with Phenotypic Screening
AbstractThere are no disease-modifying drugs for any old age associated neurodegenerative disease or stroke. This is at least in part due to the failure of drug developers to recognize that the vast majority of neurodegenerative diseases arise from a confluence of multiple toxic insults that accumulate during normal aging and interact with genetic and environmental risk factors. Thus, it is unlikely that the current single target approach based upon rare dominant mutations or even a few preselected targets is going to yield useful drugs for these conditions. Therefore, the identification of drug candidates for neurodegeneration should be based upon their efficacy in phenotypic screening assays that reflect the biology of the aging brain, not a single, preselected target. It is argued here that this approach to drug discovery is the most likely to produce safe and effective drugs for neurodegenerative diseases.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 1988 · 27 citations · open access
Familial Alzheimer's Disease
AbstractA family with familial Alzheimer's disease (FAD) inherited as an apparent autosomal dominant trait is presented. Twelve individuals (6 females; 6 males) in 4 generations were affected. The disease had its onset in the late 30's, early 40's with death by age 50. Although FAD which appears to be transmitted as an autosomal dominant trait is relatively rare, such families must be identified and carefully counselled with respect to recurrence risks for subsequent generations. In this family, there are currently 20 members of Generation IV, aged 15-37, and 9 members of Generation V, aged 1-11. The majority of these individuals appear to have a 50% risk for developing this disease.
bioRxiv (Cold Spring Harbor Laboratory) · 2017 · 0 citations · open access
Haploinsufficiency of Parkinsonism Gene <i>SYNJ1</i> Contributes to Dopamine neuron Vulnerability in Aged Mice
AbstractAbstract Parkinson’s disease (PD) is an age-dependent neurodegenerative disorder characterized by the loss of substantia nigra dopaminergic (DAergic) neurons in ventral midbrain (MB). Identification of interactions between aging and the known risk variants is crucial to understanding the etiology of PD. Recessive mutations in SYNJ1 have recently been linked to familial early-onset atypical Parkinsonism. We now show an age-dependent decline of SYNJ1 expression in the striatum as well as in striatal DAergic terminals of aged mice. Heterozygous deletion of SYNJ1 in mice causes selective elevation of PIP 2 in the MB, and manipulation of PIP 2 levels also impairs synaptic vesicle recycling preferentially in MB neurons. SYNJ1 +/− mice display progressive PD-like behavioral alterations and DAergic terminal degeneration. Furthermore, we found down-regulation of human SYNJ1 transcripts in a subset of sporadic PD brains, corroborating the role of an age-dependent decrease in SYNJ1 in predisposing DAergic neuron vulnerability and PD pathogenesis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
